Concert Pharmaceuticals
Aug 8, 2017

Concert Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Company Update

Conference Call Scheduled Today at 8:30 a.m. EDT

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2017.

"We are very pleased that we have closed the CTP-656 asset purchase agreement with Vertex, which resulted in a payment to Concert of $160 million in July. We believe our transaction with Vertex provides the optimal pathway to rapidly advance the development of CTP-656 for the benefit of cystic fibrosis patients," said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals, Inc. "The Vertex transaction significantly extends our cash runway and we expect the proceeds will allow us to advance CTP-543 into pivotal testing as well as broaden our proprietary development pipeline. We are excited about Concert's prospects, with our near-term focus on rapidly advancing CTP-543 through the Phase 2a trial for the treatment of alopecia areata. We are also assessing the potential to address additional autoimmune indications with CTP-543."

Recent Business Highlights and Upcoming Milestones

Second Quarter 2017 Financial Results

Conference Call and Webcast

The Company will host a conference call and webcast today at 8:30 a.m. EDT to provide an update on the company and discuss second quarter financial results. To access the conference call, please dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International) five minutes prior to the start time.

A live webcast of Concert's presentation may be accessed in the Investors section of the Company's website at Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Concert's website for three months.

- Financial Tables to Follow -

Concert Pharmaceuticals, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)

Three Months
Ended June 30,

Six Months Ended
June 30,

2017       2016 2017       2016
License and research and development revenue $ 15   $ 71   $ 35   $ 127  
Total revenue 15   71   35   127  
Operating expenses:
Research and development 7,285 9,816 15,522 20,269
General and administrative 5,707   3,828   10,960   7,405  
Total operating expenses 12,992   13,644   26,482   27,674  
Loss from operations (12,977 ) (13,573 ) (26,447 ) (27,547 )
Interest and other income (expense), net (50 ) 132   87   226  
Net loss (13,027 ) (13,441 ) (26,360 ) (27,321 )
Net loss per share applicable to common stockholders - basic and diluted $ (0.58 ) $ (0.60 ) $ (1.17 ) $ (1.23 )
Weighted-average number of common shares used in net loss per share applicable to common stockholders - basic and diluted 22,579   22,217   22,479   22,208  
Concert Pharmaceuticals, Inc.
Summary Balance Sheet Data
(in thousands)

June 30, 2017


December 31,

Cash and cash equivalents $ 27,591   $ 40,555
Investments, available for sale 75,829 55,630
Working capital 100,152 92,159
Total assets 108,622 100,395
Deferred revenue 10,025 10,050
Loan payable, net of discount 29,188
Total stockholders' equity $ 64,381 $ 85,594

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to address unmet patient needs. The Company's approach starts with approved drugs in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert has a broad pipeline of innovative medicines targeting autoimmune and inflammatory diseases and central nervous systems (CNS) disorders. For more information please visit

Cautionary Note on Forward Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements about our expectations for clinical development of CTP-543, the sufficiency of our cash, cash equivalents and investments to fund our operations and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission and in other filings that we make with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update any forward-looking statements included in this press release.

Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals, Inc.
Justine Koenigsberg (investors), 781-674-5284
The Yates Network
Kathryn Morris (media), 845-635-9828

Source: Concert Pharmaceuticals, Inc.

News Provided by Acquire Media